# Delaware Clinical and Translational Research ACCEL Program-Tracking and Eval Core

> **NIH NIH U54** · UNIVERSITY OF DELAWARE · 2020 · $141,210

## Abstract

Abstract—Tracking & Evaluation (T&E)
The Tracking and Evaluation (T&E) Key Component Activity (KCA) of the Delaware Clinical and Translational
(DE-CTR) ACCEL Program will define and facilitate the ongoing success of this complex research infrastructure
program. The major thrust of T&E activities will move beyond the initial accounting of research productivity, which
has been high during the first four years of the program, and focus during the renewal period on new initiatives, the
quality of integration among KCAs, and the overall impact of the ACCEL program. The Specific Aims of T&E are to: 1)
Developmentally define metrics that guide data collection, analysis, and reporting for each KCA to aid ACCEL Lead-
ership in directing program improvement, expansion and efficient use of resources; 2) Monitor and report progress
towards KCA Specific Aims and overall program accomplishments delivered via standardized reports and real-time
web-based interfaces; 3) Assure quality of T&E activities by monitoring processes and products, and by implementing
process improvements to reduce errors and improve efficiency; and 4) Develop and share best practices in tracking
and evaluation across institutions and in close partnership with other IDeA programs, including the National CTR
Evaluators Group, and the South Carolina Clinical and Translational Research Institute (SCTR). To achieve these
aims, in addition to the Overall ACCEL Specific Aims, we will utilize Liaisons representing each institution and each
KCA. We will collect KCA-specific metrics that provide feedback to ACCEL members, leadership, advisory council
members, and NIH staff. These evaluation data will define the degree to which we increase communication, expand
interdisciplinary and inter-institutional collaborations, optimize decision-making, and facilitate resource-sharing.
We will also address the degree to which ACCEL increases capacity in areas of need and opportunity, improves con-
nections with the community, and expands collaborations and infrastructure to Delaware State University. Impor-
tantly, during this renewal period we will enhance the role of T&E collaborators at the Medical University of South
Carolina (MUSC). Their expertise will allow us to more effectively incorporate Results Based Accountability, Utili-
zation Focused Evaluation, Developmental Evaluation Theory, and Lean Six Sigma methodology into T&E, and will
facilitate adoption of CTSA-based initiatives. To ensure that the quality of feedback provided by T&E is consistently
high and relevant to the needs of users and leadership, we will call upon the expertise of MUSC Liaisons to provide
objective quality assurance of T&E activities. We anticipate, based the experience of ACCEL during this first funding
period, that a continued focus on strengthening cross-institutional and cross-disciplinary efforts in our highly collab-
orative culture will facilitate further effective program building and use of resources in support of c...

## Key facts

- **NIH application ID:** 9988451
- **Project number:** 5U54GM104941-08
- **Recipient organization:** UNIVERSITY OF DELAWARE
- **Principal Investigator:** STUART A. BINDER-MACLEOD
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $141,210
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9988451

## Citation

> US National Institutes of Health, RePORTER application 9988451, Delaware Clinical and Translational Research ACCEL Program-Tracking and Eval Core (5U54GM104941-08). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9988451. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*